The Difficult Management of Depressive Symptoms in a Patient with Myasthenia Gravis: A Case Report
DOI:
https://doi.org/10.62486/agsalud2025113Keywords:
Myasthenia gravis, Depression, PsychotropicsAbstract
Introduction: Depression in patients with Myasthenia Gravis (MG) can be multifactorial, involving biological, psychological, and social factors. Depressive manifestations may arise as a result of the emotional impact of a chronic and potentially disabling condition, as well as from neurobiological changes associated with the disease or immunosuppressive treatment.
Method: In this article, we report a case of a 51-year-old man diagnosed with MG and concomitant depressive symptoms. Treatment was initiated with sertraline 150 mg/day and trazodone 50 mg/day.
Results: The choice of psychotropics should be made with caution, opting for drugs with a lower likelihood of affecting neuromuscular function. SSRIs are the most effective drugs for treating depression in patients with MG, and it is advisable to avoid drugs with anticholinergic effects, such as tricyclics and haloperidol.
Conclusion: Caution is important when prescribing psychotropic medications to patients with MG due to the risk of affecting neuromuscular transmission
References
1. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol [Internet]. 2015 [Accessed: 04/04/2024];14(10):1023-36. Available in: https://doi.org/10.1016/S1474-4422(15)00145-3.
2. Engel AG. Myasthenia gravis and myasthenic syndromes. Ann Neurol [Internet]. 1984 [Accessed: 04/04/2024];16(5):519-34. Available in: https://doi.org/10.1002/ana.410160502.
3. DeWilde S, et al. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open [Internet]. 2023 [Accessed: 10/04/2024];13(1). Available in: https://doi.org/10.1136/bmjopen-2022-066445.
4. Burns TM, et al. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve [Internet]. 2016 [Accessed: 15/04/2024];54(6):1015-22. Available in: https://doi.org/10.1002/mus.25198.
5. Suzuki Y, et al. Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. BMJ Open [Internet]. 2011 [Accessed: 22/04/2024];1(2). Available in: https://doi.org/10.1136/bmjopen-2011-000313.
6. Gavrilov YV, et al. Depression in myasthenia gravis: a heterogeneous and intriguing entity. J Neurol [Internet]. 2020 [Accessed: 29/04/2024];267(6):1802-11. Available in: https://doi.org/10.1007/s00415-020-09767-7.
7. Hoffmann S, et al. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav [Internet]. 2016 [Accessed: 01/05/2024];6(10). Available in: https://doi.org/10.1002/brb3.538.
8. Alanazy MH. Prevalence and associated factors of depressive symptoms in patients with myasthenia gravis: a cross-sectional study of two tertiary hospitals in Riyadh, Saudi Arabia. Behav Neurol [Internet]. 2019 [Accessed: 05/05/2024];2019:1-8. Available in: https://doi.org/10.1155/2019/9367453.
9. Nadali J, et al. Prevalence of depression and anxiety among myasthenia gravis (MG) patients: A systematic review and meta-analysis. Brain Behav [Internet]. 2023 [Accessed: 05/05/2024];13(1). Available in: https://doi.org/10.1002/brb3.2840.
10. Twork S, Wiesmeth S, Klewer J, et al. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes [Internet]. 2010 [Accessed: 12/05/2024];8:129. Available in: https://doi.org/10.1186/1477-7525-8-129.
11. Brusa C, et al. Psychopharmacological treatments for mental disorders in patients with neuromuscular diseases: A scoping review. Brain Sci [Internet]. 2022 [Accessed: 18/05/2024];12(2):176. Available in: https://doi.org/10.3390/brainsci12020176.
12. Schwartz ML, Cahill R. Psychopathology associated with myasthenia gravis and its treatment by psychotherapeutically oriented group counseling. J Chron Dis [Internet]. 1971 [Accessed: 30/05/2024];24:543-52. Available in: https://doi.org/10.1016/0021-9681(71)90003-2.
13. Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis. CNS Drugs [Internet]. 2007 [Accessed: 03/06/2024];21:473-81. Available in: https://doi.org/10.2165/00023210-200721060-00004.
14. Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci [Internet]. 2014 [Accessed: 11/06/2024];11(3-4):37-42. Available in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008291/.
15. Trillenberg P, et al. Worsening of myasthenia due to antiepileptic, antipsychotic, antidepressant, and sedative medication: An estimation of risk based on reporting frequency. Eur J Neurol [Internet]. 2021 [Accessed: 14/06/2024];28(7):2349-56. Available in: https://doi.org/10.1111/ene.14773.
16. Kramer M. Hypnotic medication in the treatment of chronic insomnia: non nocere! Doesn't anyone care? Sleep Med Rev [Internet]. 2000 [Accessed: 20/06/2024];4(6):529-41. Available in: https://doi.org/10.1053/smrv.2000.0122.
17. Lipton ID. Myasthenia gravis unmasked by lithium carbonate. Pande AC, Grunhaus LJ. ECT for depression in the presence of [letter]. J Clin Psychopharmacol [Internet]. 1987 [Accessed: 29/06/2024];7:57. Available in: https://doi.org/10.1097/00004714-198702000-00017.
18. Richelson E. Pharmacology of antidepressants--characteristics of the ideal drug. Mayo Clin Proc [Internet]. 1994 [Accessed: 03/07/2024];69(11):1069-81. Available in: https://doi.org/10.1016/s0025-6196(12)61375-5.
19. Wisnu Wardhana IBG, Sri Wahyuni AA, Arimbawa K. Psychopharmacology in myasthenia gravis patients with focus on depression. Int J Res Med Sci [Internet]. 2019 [Accessed: 07/07/2024];7(8):3230-4. Available in: https://doi.org/10.18203/2320-6012.ijrms20193426.
Published
Issue
Section
License
Copyright (c) 2025 Bruno Garcia Pereira, Guilherme José Barreto Alcântara, Júlio César Garcia de Alencar, Rebeca Mendes de Paula Pessoa (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.